Report Summary 1. Report Industry Investment Rating - Not provided in the content. 2. Core Viewpoints - The RDEP represents a significant evolution in FDA's approach to ultra - rare disease drug development, emphasizing scientific flexibility and innovation while maintaining strict evidence standards [22]. - Success under the RDEP depends on strategic integration of real - world evidence, strong confirmatory evidence, and careful cooperation with regulatory agencies [24]. 3. Summary by Related Catalog RDEP Introduction - In September 2025, the FDA released the Rare Disease Evidence Principles (RDEP), a new review process for ultra - rare, genetically - defined diseases, aiming to provide more clarity and predictability [3]. - RDEP is built on the precedent of the FDA's 2023 draft guidance, using a well - controlled clinical study to prove effectiveness and provide confirmatory evidence [4]. Comparison with Existing Pathways - RDEP formalizes the FDA's previous practices in rare - disease approvals, and it supplements existing mechanisms like accelerated approval, orphan drug designation, and RDEA pilot by clarifying evidence expectations [7][8]. Eligibility for RDEP - RDEP aims to support therapy developers for diseases that meet all of the following conditions: a sponsor can prove a well - controlled study with strong evidence to establish effectiveness; the disease is caused by a known congenital genetic defect; the situation is critical, rapidly progressing, and there is no disease - modifying treatment; and fewer than 1000 patients in the US are affected [8]. Role of RWE - Before accessing the RDEP process, RWE can be used to confirm the ultra - rare prevalence threshold of a disease by combining medical claims, EHRs, genomic databases, and patient registries, and AI - driven analysis can further refine these estimates [11][12]. - Once in the RDEP process, RWE plays a core role in natural history studies, patient registries, external comparator arms, and expanded access data and case reports [15]. Patient - Centered Development - In ultra - rare diseases, patient - centered drug development is crucial, and natural history studies and registries, especially those co - designed with advocacy groups, help identify important functional changes for patients and caregivers [18]. Time Considerations - Before starting a critical trial, sponsors should submit an application to their existing IND for each protocol they want to be reviewed under RDEP, including reasonable evidence to meet the inclusion criteria and prove the drug's safety and effectiveness [21]. Conclusion - RDEP provides a customized pathway for programs less likely to meet traditional requirements, and cooperation is key to accelerating treatment for patients in need [23][24].

Industry Investment Rating - The industry investment rating is "Outperform" and is maintained [1] Core Insights - The report highlights the strong growth potential in the AI-assisted precision medicine sector, particularly through companies like Tempus AI, which is expected to achieve significant revenue growth and profitability by 2025 [4][6][58] - The report emphasizes the competitive advantages of Tempus AI, including its extensive proprietary data set and partnerships with major pharmaceutical companies, which are expected to drive future growth [20][54][64] Summary by Sections Industry Overview - The closing index level is 5480.49, with a 52-week high of 5841.52 and a low of 3963.29 [1] Tempus AI Performance - Tempus AI's revenue for 2024 is projected at $693 million, reflecting a year-over-year increase of 30.38%, with a Non-GAAP gross margin of 58.3% [4][25] - The company expects to achieve an adjusted EBITDA of $5 million in 2025, marking its first positive EBITDA [58] Investment Logic - Short-term: The gene testing business is expected to benefit from increased penetration of xT CDs, leading to higher average selling prices (ASP) and gross margins [5] - Long-term: The data business has a strong moat and high customer retention, with a net retention rate of 140% [5][64] Valuation Status - Tempus AI holds a leading position in the precision medicine and real-world data (RWD) sectors, with a market capitalization of $15.91 billion and a forward price-to-sales ratio of 12.63 for 2025 [6] Domestic Market Developments - Companies like RunDa Medical and JiaHe MeiKang are actively developing AI-driven healthcare solutions, indicating a growing trend in the domestic AI healthcare market [7][8] Investment Recommendations - The report suggests focusing on companies such as RunDa Medical, JiaHe MeiKang, WeiNing Health, and others as potential investment opportunities in the AI healthcare sector [10]

Core Insights - A long-term real-world study conducted over 11 years confirms that the pneumococcal conjugate vaccine (PCV) effectively prevents pneumococcal diseases and significantly reduces antibiotic resistance [1][2] - The study fills a critical evidence gap regarding the long-term public health impact of PCV13 in China, providing essential data for optimizing immunization strategies [1] Summary by Sections Vaccine Efficacy - The study found that the serotypes covered by PCV13 accounted for 96.8% of invasive isolates, indicating its effectiveness against major pathogenic types in China [2] - The proportion of vaccine-covered serotypes in overall pneumococcal diseases decreased significantly from 92.8% to 59.2%, demonstrating a clear downward trend and the protective effect of the vaccine [2] - Notably, the highly resistant serotype 19F dropped from 59.2% to 14.4%, leading to a reduction in the non-sensitivity rate of beta-lactam antibiotics from 16.0% to 2.4% [2] Public Health Implications - The research highlights the public health value of PCV vaccination in reducing the transmission of highly pathogenic and resistant serotypes, proving it to be a powerful tool against invasive pneumococcal disease (IPD) and antibiotic resistance [2] - The study serves as a "real-world report card," providing scientific evidence for vaccine strategies while addressing the limitations of traditional clinical trials [2] Global Context and Challenges - Pfizer's experience with PCV vaccines globally shows that over 300 million children have been protected from IPD, with significant reductions in IPD incidence reported in various countries [4] - In China, the burden of pneumococcal disease in children under five is severe, with over 560,000 cases annually and approximately 8,000 deaths [4] Vaccination Coverage and Future Directions - There is a significant gap in PCV vaccination rates in China, with an estimated coverage of only 7.3% compared to the global average of 47.9% in 2019 [5] - Continuous monitoring and iterative research and development are essential to address the evolving challenges posed by changing serotype distributions and to enhance vaccine efficacy [5] Technological Innovations - Pfizer emphasizes the importance of ongoing innovation in vaccine development, highlighting the transition from PCV7 and PCV13 to higher-valent vaccines like PCV20, which address complex technical challenges [5] - The use of CRM197 as a carrier protein in higher-valent vaccines has proven to be scientifically sound and advantageous, aiming to provide comprehensive protection against pneumococcal diseases [5]